1
|
Sadeghi Hokmabadi E, Daei Sorkhabi A, Sarkesh A, Sadigh-Eteghad S, Mehdizadehfar E, Sadeghpoor Y, Farhoudi M. Efficacy and safety of direct oral anticoagulants versus warfarin in the treatment of cerebral venous sinus thrombosis. Acta Neurol Belg 2024:10.1007/s13760-024-02586-x. [PMID: 38985242 DOI: 10.1007/s13760-024-02586-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2023] [Accepted: 05/14/2024] [Indexed: 07/11/2024]
Abstract
BACKGROUND Given the evolving application and promising outcomes of direct oral anticoagulants (DOACs) in various thromboembolic conditions, we aimed to compare the efficacy and safety of DOACs with warfarin in the post-acute treatment of cerebral venous sinus thrombosis (CVST) using clinical and radiological parameters. METHODS A total of 140 CVST patients were enrolled, with 95 receiving warfarin and 45 receiving DOACs as post-acute treatment. Clinical and imaging parameters of the patients in follow-up visits were investigated, including the last modified Rankin Scale (mRS), venous thromboembolic events, CVST recurrence, mortality rate, recanalization status, and hemorrhagic events, to compare the efficacy and safety of treatment between the two groups. RESULTS At baseline, patients' assessments using two prognostic scores, ISCVT-RS and IN-REvASC, revealed that there was no statistically significant difference in the distribution of prognostic risk categories between the warfarin and DOACs groups. Following acute therapy, patients in the warfarin and DOACs groups were followed up for the median of 359 and 325 days, respectively. Analysis to compare the efficacy of warfarin and DOACs revealed no significant difference in last mRS scores, CVST recurrence rate, venous thromboembolic events, and recanalization status between the two groups. Additionally, there was no statistically significant difference in the risk of hemorrhagic events between warfarin and DOACs groups. CONCLUSION Our findings show that DOACs have comparable safety and efficacy in the post-acute treatment of CVST patients; however, large-scale randomized controlled trials are required to validate our findings.
Collapse
Affiliation(s)
- Elyar Sadeghi Hokmabadi
- Neurosciences Research Center (NSRC), Department of Neurology, Imam‑Reza hospital, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Amin Daei Sorkhabi
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Aila Sarkesh
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Saeed Sadigh-Eteghad
- Neurosciences Research Center (NSRC), Department of Neurology, Imam‑Reza hospital, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Elham Mehdizadehfar
- Neurosciences Research Center (NSRC), Department of Neurology, Imam‑Reza hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
| | - Yalda Sadeghpoor
- Neurosciences Research Center (NSRC), Department of Neurology, Imam‑Reza hospital, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Mehdi Farhoudi
- Neurosciences Research Center (NSRC), Department of Neurology, Imam‑Reza hospital, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
2
|
Dubé MC, Ducroux C, Daneault N, Deschaintre Y, Jacquin G, Odier C, Stapf C, Poppe AY, Romanelli G, Gioia LC. Characteristics of Ischemic Stroke Despite Oral Anticoagulant Use For Atrial Fibrillation. Can J Neurol Sci 2024:1-4. [PMID: 38232961 DOI: 10.1017/cjn.2024.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2024]
Abstract
Oral anticoagulation (OAC) prevents stroke in atrial fibrillation, yet a residual stroke risk remains. In this single-center retrospective analysis of acute ischemic stroke patients despite OAC, suboptimal OAC treatment is common (30%: inappropriate dosing (17%); patient non-adherence (13%)). Other causes of stroke included OAC interruption (14.5%), a competing stroke mechanism (11.0%), and undetermined breakthrough stroke in 44.5%. Overall, easily modifiable causes of ischemic stroke despite OAC are common. Accordingly, strategies to improve treatment compliance, including appropriate dosing along with guideline-based risk factor and periprocedural OAC management, should be emphasized to improve secondary stroke prevention in this patient population.
Collapse
Affiliation(s)
- Marie-Christine Dubé
- Department of Neurosciences, Faculté de médecine, Université de Montréal, Montréal, QC, Canada
- Department of Medicine (Neurology), Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
| | - Célina Ducroux
- Department of Neurosciences, Faculté de médecine, Université de Montréal, Montréal, QC, Canada
- Department of Medicine (Neurology), Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
| | - Nicole Daneault
- Department of Neurosciences, Faculté de médecine, Université de Montréal, Montréal, QC, Canada
- Department of Medicine (Neurology), Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
- Neurovascular Group, Neurosciences Axis, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada
| | - Yan Deschaintre
- Department of Neurosciences, Faculté de médecine, Université de Montréal, Montréal, QC, Canada
- Department of Medicine (Neurology), Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
- Neurovascular Group, Neurosciences Axis, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada
| | - Grégory Jacquin
- Department of Neurosciences, Faculté de médecine, Université de Montréal, Montréal, QC, Canada
- Department of Medicine (Neurology), Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
- Neurovascular Group, Neurosciences Axis, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada
| | - Céline Odier
- Department of Neurosciences, Faculté de médecine, Université de Montréal, Montréal, QC, Canada
- Department of Medicine (Neurology), Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
- Neurovascular Group, Neurosciences Axis, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada
| | - Christian Stapf
- Department of Neurosciences, Faculté de médecine, Université de Montréal, Montréal, QC, Canada
- Department of Medicine (Neurology), Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
- Neurovascular Group, Neurosciences Axis, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada
| | - Alexandre Y Poppe
- Department of Neurosciences, Faculté de médecine, Université de Montréal, Montréal, QC, Canada
- Department of Medicine (Neurology), Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
- Neurovascular Group, Neurosciences Axis, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada
| | - Giovanni Romanelli
- Department of Medicine (Cardiology), Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
| | - Laura C Gioia
- Department of Neurosciences, Faculté de médecine, Université de Montréal, Montréal, QC, Canada
- Department of Medicine (Neurology), Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
- Neurovascular Group, Neurosciences Axis, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada
| |
Collapse
|
3
|
Adelakun AR, Turgeon RD, De Vera MA, McGrail K, Loewen PS. Oral anticoagulant switching in patients with atrial fibrillation: a scoping review. BMJ Open 2023; 13:e071907. [PMID: 37185198 PMCID: PMC10151984 DOI: 10.1136/bmjopen-2023-071907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/17/2023] Open
Abstract
INTRODUCTION Oral anticoagulants (OACs) prevent stroke in patients with atrial fibrillation (AF). Several factors may cause OAC switching. OBJECTIVES To examine the phenomenon of OAC switching in patients with AF, including all available evidence; frequency and patterns of switch, clinical outcomes, adherence, patient-reported outcomes, reasons for switch, factors associated with switch and evidence gaps. DESIGN Scoping review. DATA SOURCES MEDLINE, Embase and Web of Science, up to January 2022. RESULTS Of the 116 included studies, 2/3 examined vitamin K antagonist (VKA) to direct-acting OAC (DOAC) switching. Overall, OAC switching was common and the definition of an OAC switch varied across. Switching from VKA to dabigatran was the most prevalent switch type, but VKA to apixaban has increased in recent years. Patients on DOAC switched more to warfarin than to other DOACs. OAC doses involved in the switches were hardly reported and patients were often censored after the first switch. Switching back to a previously taken OAC (frequently warfarin) occurred in 5%-21% of switchers.The risk of ischaemic stroke and gastrointestinal bleeding in VKA to DOAC switchers compared with non-switchers was conflicting, while there was no difference in the risk of other types of bleeding. The risk of ischaemic stroke in switchers from DOAC versus non-switchers was conflicting. Studies evaluating adherence found no significant changes in adherence after switching from VKA to DOAC, however, an increase in satisfaction with therapy were reported. Reasons for OAC switch, and factors associated with OAC switch were mostly risk factors for stroke and bleeding. Clinical outcomes, adherence and patient-reported outcomes were sparse for switches from DOACs. CONCLUSIONS OAC switching is common in patients with AF and patients often switch back to an OAC they have previously been on. There are aspects of OAC switching that have received little study, especially in switches from DOACs.
Collapse
Affiliation(s)
- Adenike R Adelakun
- Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
- Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Science, The University of British Columbia, Vancouver, British Columbia, Canada
| | - Ricky D Turgeon
- Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
- Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Science, The University of British Columbia, Vancouver, British Columbia, Canada
| | - Mary A De Vera
- Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
- Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Science, The University of British Columbia, Vancouver, British Columbia, Canada
| | - Kimberlyn McGrail
- Centre for Health Services and Policy Research, The University of British Columbia, Vancouver, British Columbia, Canada
- School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada
| | - Peter S Loewen
- Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
- Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Science, The University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
4
|
D'Anna L, Filippidis FT, Harvey K, Korompoki E, Veltkamp R. Ischemic stroke in oral anticoagulated patients with atrial fibrillation. Acta Neurol Scand 2022; 145:288-296. [PMID: 34766621 DOI: 10.1111/ane.13552] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Revised: 10/25/2021] [Accepted: 10/31/2021] [Indexed: 01/02/2023]
Abstract
BACKGROUND Ischemic strokes in orally anticoagulated patients pose challenges for acute management and secondary prevention but the characteristics of these strokes are poorly understood. We examined the clinical and imaging features, the presumed underlying etiology and the subsequent antithrombotic management. METHODS We analyzed a consecutive series of patients enrolled into the EIDASAF study, a single center, observational study of ischemic stroke patients with a diagnosis atrial fibrillation (AF) prior to the index event who had been admitted to the Hyperacute Stroke Unit of Imperial College London between 2010 and 2017. We compared patients with oral anticoagulation therapy prior admission (OACprior ) with those without anticoagulation (OACnaive ). Brain imaging was analyzed centrally. RESULTS 763 patients were included in the analysis. 481 (63%) were OACnaive while 282 (37%) were OACprior . Patients with OACprior were younger, more often had a previous history of stroke or transient ischemic attack (TIA), and more often suffered from hypertension and diabetes. In OACnaive, patients, large and deep middle cerebral artery infarcts occurred more often than in OACprior patients. The groups differed significantly in the distribution of competing etiologies underlying their stroke. At discharge, OACprior more frequently were (re)-anticoagulated compared to OACnaive patients. Within the OACprior group, patients with recurrent strokes did not differ from those with a first stroke regarding clinical characteristics and pattern of cerebral infarction but they were less frequently anticoagulated. CONCLUSIONS Ischemic strokes on OAC represent a significant proportion of AF-related strokes. There is an unmet need to better understand the causes underlying these strokes and to optimize the medical management.
Collapse
Affiliation(s)
- Lucio D'Anna
- Department of Stroke and Neuroscience Charing Cross Hospital Imperial College Healthcare NHS Trust London UK
- Department of Brain Sciences Imperial College London London UK
| | - Filippos T. Filippidis
- Department of Primary Care and Public Health School of Public Health Imperial College London London UK
| | - Kirsten Harvey
- Department of Brain Sciences Imperial College London London UK
| | - Eleni Korompoki
- Department of Brain Sciences Imperial College London London UK
| | - Roland Veltkamp
- Department of Brain Sciences Imperial College London London UK
- Department of Neurology Alfried‐Krupp Krankenhaus Essen Germany
- Department of Neurology University Hospital Heidelberg Heidelberg Germany
| |
Collapse
|